Targeting the Vascular Endothelium in the Treatment of COVID-19

Tatsiana Suvorava; Wayne Kaesemeyer

doi:10.1097/FJC.0000000000000932

Targeting the Vascular Endothelium in the Treatment of COVID-19

J Cardiovasc Pharmacol. 2021 Jan 1;77(1):1-3. doi: 10.1097/FJC.0000000000000932.

Authors

Tatsiana Suvorava¹, Wayne Kaesemeyer²

Affiliations

¹ Institute of Pharmacology and Clinical Pharmacology, University Hospital, Duesseldorf, Germany; and.
² Augusta Hypertension PC, Chapel Hill, North Carolina.

PMID: 33079828
DOI: 10.1097/FJC.0000000000000932

Abstract

The involvement of the vascular endothelium in the complications of coronavirus disease 2019 is now recognized. Chief among these are pulmonary endotheliitis, cytokine storm, endotoxic shock, and cardiovascular collapse. This Perspectives article is focused on therapeutical strategies to reduce the risk of these complications by targeting the vascular endothelium as a part of the overall treatment of coronavirus disease 2019.

Publication types

Review

MeSH terms

Angiotensin II / administration & dosage
Angiotensin-Converting Enzyme 2 / antagonists & inhibitors
Angiotensin-Converting Enzyme 2 / metabolism
COVID-19 / metabolism*
COVID-19 Drug Treatment
Cytokine Release Syndrome / drug therapy
Cytokine Release Syndrome / metabolism*
Drug Delivery Systems / methods*
Drug Delivery Systems / trends
Endothelium, Vascular / drug effects
Endothelium, Vascular / metabolism*
Humans

Substances

Angiotensin II
ACE2 protein, human
Angiotensin-Converting Enzyme 2